{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal wharton s jelly",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "ResultsFirstSubmitDate",
                  "ResultsFirstSubmitQCDate",
                  "RetractionPMID",
                  "RetractionSource",
                  "SamplingMethod",
                  "SecondaryId",
                  "SecondaryIdDomain",
                  "SecondaryIdLink",
                  "SecondaryIdType",
                  "SecondaryOutcomeDescription",
                  "SecondaryOutcomeMeasure",
                  "SecondaryOutcomeTimeFrame",
                  "SeeAlsoLinkLabel",
                  "SeeAlsoLinkURL",
                  "SeriousEventAssessmentType",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [],
                        "SecondaryOutcomeMeasure": [],
                        "SecondaryOutcomeTimeFrame": [],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 2,
                        "ResultsFirstSubmitDate": [],
                        "ResultsFirstSubmitQCDate": [],
                        "RetractionPMID": [],
                        "RetractionSource": [],
                        "SamplingMethod": [],
                        "SecondaryId": [],
                        "SecondaryIdDomain": [],
                        "SecondaryIdLink": [],
                        "SecondaryIdType": [],
                        "SecondaryOutcomeDescription": [
                              "Disease progression assessed in ALSFRS-R scale (Revised Amyotrophic Lateral Sclerosis Functional Rating Scale). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 48 points",
                              "Pulmonary function decline assessed in spirometry (forced vital capacity)",
                              "Muscle strength decline",
                              "Upper motor neuron function assessed in UMNS scale (Upper Motor Neuron Scale). Best outcome 16 points, worst outcomes: 0 points and 48 points Minimum: 0 points Maximum: 48 points",
                              "Cognitive function assessed in ECAS (The Edinburgh Cognitive and Behavioural ALS Screen). Higher scores mean a better outcome.\n\nMinimum: 0 points Maximum: 136 points",
                              "Quality of life changes, assessed by EQ-5D questionnaire - standardized instrument for measuring generic health status. Higher scores mean a better outcome.",
                              "The change of defined cytokines, chemokines, growth factors and pNFH level assessed in the samples of CSF",
                              "The change of defined cytokines, chemokines level assessed in the samples of blood serum",
                              "The change of creatinine and p75ECD level",
                              "Muscle function changes, assessed based on EMG examination (Electrophysiological examination of the muscle - MUNIX - motor unit number estimation)",
                              "The change of the brain visualization in MRI (T1, T2 and DTI)",
                              "The number of SAE/AE and (S)AESI - defined as in Outcome 1",
                              "The number of days from patients randomization to the end of the patients participation in the trial or to the one of the following:\n\nPAV (permanent assisted ventilation)\nTracheostomy\nDeath",
                              "Percentage of deaths in the entire study population."
                        ],
                        "SecondaryOutcomeMeasure": [
                              "Disease progression",
                              "Pulmonary function decline",
                              "Muscle strength decline",
                              "Upper motor neuron function",
                              "Cognitive function",
                              "Quality of life changes",
                              "The change of defined cytokines, chemokines, growth factors and pNFH (phosphorylated neurofilament heavy chain) level in CSF (Cerebrospinal fluid)",
                              "The change of defined cytokines, chemokines level in blood",
                              "The change of creatinine and p75ECD level in urine",
                              "Muscle function changes",
                              "The change of the brain visualization",
                              "SAE (Serious Adverse Event)/AE (Adverse Event) and (S)AESI",
                              "Survival period to disease progression",
                              "Mortality rate"
                        ],
                        "SecondaryOutcomeTimeFrame": [
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU",
                              "screening and 12 month FU",
                              "screening, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 18 month FU",
                              "run-in visit (-60 day), at baseline and at 1, 2 and 6 month FU (12 month FU optional)",
                              "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "screening visit, run-in period (-60 day and -30 day), at baseline and at 1, 2, 3, 6, 9 and 12 month FU.",
                              "baseline and at 1, 2, 6 and 12 month FU",
                              "run-in visit (-60 day), 6 and 12 month FU",
                              "18 month FU",
                              "18 month FU",
                              "18 month FU"
                        ],
                        "SeeAlsoLinkLabel": [],
                        "SeeAlsoLinkURL": [],
                        "SeriousEventAssessmentType": [],
                        "NCTId": [
                              "NCT04651855"
                        ]
                  }
            ]
      }
}